
Axcella Health AXLA
Quartalsbericht 2023-Q2
hinzugefügt 03.08.2023
Axcella Health Langfristiger Schuldenstrom 2011-2026 | AXLA
Langfristiger Schuldenstrom Jährlich Axcella Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.59 M | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.59 M | 1.59 M | 1.59 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Ascendis Pharma A/S
ASND
|
14.2 M | $ 220.94 | 2.51 % | $ 5 B | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 19.7 | 2.44 % | $ 921 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Mesoblast Limited
MESO
|
3.19 M | $ 15.54 | 8.48 % | $ 10.1 B | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B | ||
|
Mirum Pharmaceuticals
MIRM
|
2.14 M | $ 90.9 | 3.44 % | $ 4.56 B | ||
|
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | ||
|
Cara Therapeutics
CARA
|
1.92 M | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
MediciNova
MNOV
|
194 K | $ 1.44 | -0.68 % | $ 70.7 M | ||
|
Autolus Therapeutics plc
AUTL
|
5.05 M | $ 1.36 | 3.03 % | $ 347 M | ||
|
CytomX Therapeutics
CTMX
|
4.24 M | $ 4.41 | 3.98 % | $ 608 M | ||
|
ChemoCentryx
CCXI
|
2.81 M | - | - | $ 3.74 B | ||
|
Merck & Co.
MRK
|
294 M | $ 118.9 | 2.17 % | $ 297 B | ||
|
Dynavax Technologies Corporation
DVAX
|
4.18 M | - | - | $ 2.02 B | ||
|
Enochian Biosciences
ENOB
|
313 K | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | ||
|
Neurocrine Biosciences
NBIX
|
56 M | $ 131.82 | 3.1 % | $ 13.1 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
547 K | $ 4.56 | 5.68 % | $ 874 M | ||
|
Homology Medicines
FIXX
|
693 K | - | 0.77 % | $ 53.4 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M |